NEUP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neuphoria Therapeutics Inc (NEUP) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is significantly deteriorating, with no positive news or trading trends to support a bullish outlook. Additionally, there are no strong technical signals or proprietary trading signals to suggest a favorable entry point.
The MACD is slightly positive but contracting, indicating weakening momentum. The RSI is neutral at 61.399, and moving averages are converging, showing no clear trend. The pre-market price is $4.73, near the R1 resistance level of $4.761, which may act as a barrier to further upward movement.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
No recent news or events to drive positive sentiment. Stock trend analysis suggests limited upside potential in the short term.
In Q2 2026, the company's revenue dropped to $0 (-100% YoY), net income fell to $1,864,092 (-195.92% YoY), EPS decreased to 0.41 (-133.33% YoY), and gross margin dropped to 0 (-100% YoY). These metrics indicate a significant decline in financial health.
No data on analyst ratings or price target changes is available.
